Method of using selective parp inhibitors to prevent or treat neurotoxicity

US6358975B1 · kind B1 · utility

Assignee

• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• Mikael ELIASSON · Nordstraße, SE
• Kenji Sampei · Baltimore, US
• Allen S. Mandir · Baltimore, US
• Patricia D. Hurn · Portland, US
• Richard J. Traystman · Ruxton, US
• Jun Bao · Shanghai, CN
• Andrew A. Pieper · Iowa City, US
• Ted M. Dawson · Baltimore, US
• Solomon H. Snyder · Baltimore, US
• Valina L. Dawson · Baltimore, US

Key dates

• Filing date: Feb 11, 2000
• Grant date: Mar 19, 2002
• Expiry date: Feb 11, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/536
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Neutral tissue damage resulting for ischemia and reperfusion injury or neurodegenerative diseases can be prevented by administering therapeutically effective amounts of certain selective inhibitors of poly(ADP-ribose)polymerase. The inhibitors can be administered intravenously, intraperitoneally, intramuscularly, intraventricularly, or orally. They can be administered as a capsule or tablet containing single or divided dose. Alternatively, the inhibitors can be administered as a sterile solution, suspension or emulsion.